Basilea Pharmaceutica AG BPMUF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.02% | 5.77% | 5.93% | 24.59% | 51.70% |
| Total Other Revenue | 131.91% | 161.45% | 196.77% | 230.18% | 313.69% |
| Total Revenue | 14.41% | 18.99% | 18.49% | 35.94% | 62.20% |
| Cost of Revenue | 31.09% | 35.57% | 33.69% | 17.80% | 3.77% |
| Gross Profit | -4.90% | -0.79% | -0.45% | 73.02% | 365.71% |
| SG&A Expenses | 17.02% | 21.42% | 19.60% | 13.98% | 9.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.18% | 32.62% | 30.72% | 17.02% | 4.83% |
| Operating Income | -14.38% | -10.98% | -10.46% | 138.66% | 1,229.08% |
| Income Before Tax | -11.04% | -13.41% | -19.29% | 158.70% | 621.25% |
| Income Tax Expenses | 2,187.64% | 174.85% | 134.39% | 118.39% | 97.48% |
| Earnings from Continuing Operations | -20.96% | -32.19% | -44.74% | 49.64% | 9,803.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.96% | -32.19% | -44.74% | 49.64% | 9,803.52% |
| EBIT | -14.38% | -10.98% | -10.46% | 138.66% | 1,229.08% |
| EBITDA | -14.57% | -10.58% | -9.31% | 129.28% | 1,838.31% |
| EPS Basic | -22.13% | -33.18% | -45.45% | 48.80% | 8,632.55% |
| Normalized Basic EPS | -12.75% | -14.35% | -19.29% | 160.15% | 618.68% |
| EPS Diluted | -19.88% | -30.65% | -42.63% | 56.54% | 2,372.16% |
| Normalized Diluted EPS | -11.53% | -10.51% | -15.46% | 184.46% | 539.03% |
| Average Basic Shares Outstanding | 1.12% | 1.31% | 1.37% | 1.25% | 1.14% |
| Average Diluted Shares Outstanding | 0.92% | -2.00% | -1.88% | 2.33% | 6.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |